Maraviroc (Selzentry, Celsentri)

Published September 24, 2007; Updated October 19, 2011
Susa Coffey, MD
http://hivinsite.ucsf.edu/InSite?page=ar-06-01
Selected Reference
7. Gulick RM, van der Ryst E, Lampiris H, et al. Efficacy and safety of once-daily (QD) compared with twice-daily (BID) maraviroc plus optimized background therapy (OBT) in treatment-experienced patients infected with CCR5-tropic-HIV-1: 24-week combined analysis of the MOTIVATE 1 and 2 studies. In: Program and abstracts of the 4th IAS Conference on HIV Pathogenesis, Treatment and Prevention; July 23-25, 2007; Sydney, Australia. Abstract WEPEB116LB.